Gomez DR, et al. - In patients with stage IV non-small-cell lung cancer (NSCLC), with three or less metastases, and no progression at 3 or more months following front-line systemic therapy, researchers assessed local consolidative therapy (LCT) vs maintenance therapy or observation (MT/O) for progression-free survival (PFS), overall survival (OS), toxicity, and the appearance of new lesions. Participants were randomly allocated (1:1) to MT/O or to LCT to all active disease sites. Two sided analyses were performed, and P values less than .10 were considered significant. Compared to MT/O, prolonged PFS and OS were achieved with LCT in patients with oligometastatic NSCLC that did not progress following front-line systemic therapy. Findings revealed no additional grade 3 or greater toxicities were present.